NCT06492759 2026-04-17
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
Emory University
Phase 2 Recruiting
Clinical Trials
7 trialsNCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT03801369 2026-02-25
AMTEC IIT: Phase 2 Multiarm Study in TNBC
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT06351332 2026-01-12
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT02456857 2024-02-13
Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03544125 2020-11-20
Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer
OHSU Knight Cancer Institute
Phase 1 Completed
NCT03644589 2019-04-26
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer
University of Washington
Phase 2 Withdrawn